BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 27596691)

  • 1. Racial Disparities in Active Surveillance for Prostate Cancer.
    Krishna S; Fan Y; Jarosek S; Adejoro O; Chamie K; Konety B
    J Urol; 2017 Feb; 197(2):342-349. PubMed ID: 27596691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study.
    Schenk JM; Newcomb LF; Zheng Y; Faino AV; Zhu K; Nyame YA; Brooks JD; Carroll PR; Cooperberg MR; Dash A; Filson CP; Gleave ME; Liss M; Martin FM; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW
    J Urol; 2020 Apr; 203(4):727-733. PubMed ID: 31651227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk Prostate Cancer With Active Surveillance.
    Nelson TJ; Javier-DesLoges J; Deka R; Courtney PT; Nalawade V; Mell L; Murphy J; Parsons JK; Rose BS
    JAMA Netw Open; 2021 May; 4(5):e219452. PubMed ID: 33999164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer.
    Shavers VL; Brown M; Klabunde CN; Potosky AL; Davis W; Moul J; Fahey A
    Med Care; 2004 Mar; 42(3):239-50. PubMed ID: 15076823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer.
    Shavers VL; Brown ML; Potosky AL; Klabunde CN; Davis WW; Moul JW; Fahey A
    J Gen Intern Med; 2004 Feb; 19(2):146-55. PubMed ID: 15009794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy.
    Leapman MS; Freedland SJ; Aronson WJ; Kane CJ; Terris MK; Walker K; Amling CL; Carroll PR; Cooperberg MR
    J Urol; 2016 Nov; 196(5):1408-1414. PubMed ID: 27352635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US.
    Washington SL; Jeong CW; Lonergan PE; Herlemann A; Gomez SL; Carroll PR; Cooperberg MR
    JAMA Netw Open; 2020 Dec; 3(12):e2031349. PubMed ID: 33369661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Racial and Ethnic Variation in Receipt and Intensity of Active Surveillance for Older Patients With Localized Prostate Cancer.
    Basourakos SP; An A; Davuluri M; Pinheiro LC; Al Awamlh BAH; Borregales LD; Luan D; Tamimi RM; Hu JC; Kensler KH
    Urol Pract; 2024 May; 11(3):538-546. PubMed ID: 38640417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between African American Race and Clinical Outcomes in Men Treated for Low-Risk Prostate Cancer With Active Surveillance.
    Deka R; Courtney PT; Parsons JK; Nelson TJ; Nalawade V; Luterstein E; Cherry DR; Simpson DR; Mundt AJ; Murphy JD; D'Amico AV; Kane CJ; Martinez ME; Rose BS
    JAMA; 2020 Nov; 324(17):1747-1754. PubMed ID: 33141207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients.
    Bandini M; Preisser F; Nazzani S; Marchioni M; Tian Z; Mazzone E; Graefen M; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
    Eur Urol Oncol; 2018 Aug; 1(3):215-222. PubMed ID: 31102624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer.
    Mahal BA; Ziehr DR; Aizer AA; Hyatt AS; Sammon JD; Schmid M; Choueiri TK; Hu JC; Sweeney CJ; Beard CJ; D'Amico AV; Martin NE; Lathan C; Kim SP; Trinh QD; Nguyen PL
    Urol Oncol; 2014 Nov; 32(8):1285-91. PubMed ID: 24846344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
    Loeb S; Berglund A; Stattin P
    J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Racial Differences in Treatment Decision-Making for Men with Clinically Localized Prostate Cancer: a Population-Based Study.
    Xu J; Janisse J; Ruterbusch J; Ager J; Schwartz KL
    J Racial Ethn Health Disparities; 2016 Mar; 3(1):35-45. PubMed ID: 26896103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation in use of active surveillance among men undergoing expectant treatment for early stage prostate cancer.
    Filson CP; Schroeck FR; Ye Z; Wei JT; Hollenbeck BK; Miller DC
    J Urol; 2014 Jul; 192(1):75-80. PubMed ID: 24518783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active Surveillance for Men with Intermediate Risk Prostate Cancer.
    Agrawal V; Ma X; Hu JC; Barbieri CE; Nagar H
    J Urol; 2021 Jan; 205(1):115-121. PubMed ID: 32658588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population-based assessment of determining predictors for quality of prostate cancer surveillance.
    Chamie K; Williams SB; Hershman DL; Wright JD; Nguyen PL; Hu JC
    Cancer; 2015 Dec; 121(23):4150-7. PubMed ID: 26307939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Income inequality and treatment of African American men with high-risk prostate cancer.
    Ziehr DR; Mahal BA; Aizer AA; Hyatt AS; Beard CJ; D Amico AV; Choueiri TK; Elfiky A; Lathan CS; Martin NE; Sweeney CJ; Trinh QD; Nguyen PL
    Urol Oncol; 2015 Jan; 33(1):18.e7-18.e13. PubMed ID: 25306287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population-Based Assessment of Determining Treatments for Prostate Cancer.
    Chamie K; Williams SB; Hu JC
    JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System.
    Yamoah K; Lee KM; Awasthi S; Alba PR; Perez C; Anglin-Foote TR; Robison B; Gao A; DuVall SL; Katsoulakis E; Wong YN; Markt SC; Rose BS; Burri R; Wang C; Aboiralor O; Fink AK; Nickols NG; Lynch JA; Garraway IP
    JAMA Netw Open; 2022 Jan; 5(1):e2144027. PubMed ID: 35040965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison by Race of Conservative Management for Low-Risk and Intermediate-Risk Prostate Cancers in Veterans From 2004 to 2018.
    Parikh RB; Robinson KW; Chhatre S; Medvedeva E; Cashy JP; Veera S; Bauml JM; Fojo T; Navathe AS; Malkowicz SB; Mamtani R; Jayadevappa R
    JAMA Netw Open; 2020 Sep; 3(9):e2018318. PubMed ID: 32986109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.